EXPLAINED: 3 - The Real Truth

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

International Business Times · Jul 23

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Medical Daily · Jul 23

What You Need to Know Ahead of Eli Lilly's Earnings Release

Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Jul 22

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

International Business Times · Jul 16

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

Barchart · Jul 16

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect…

The Economic Times · Jul 16

A Shot Every Two Weeks Instead of Weekly: New GLP-1 Drug Shows Strong Trial Results

A new biweekly GLP-1 drug called bofanglutide showed strong blood sugar and weight loss results in a Phase 2b trial. Monthly injectables and oral pills are also in the pipeline.

Medical Daily · Jul 9

A New FDA-Approved Oral Weight Loss Pill Requires No Fasting: What Makes Foundayo Different from Other GLP-1 Drugs

FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4%. Here's the breakdown.

Medical Daily · Jul 7

Eli Lilly just placed a $40 million bet on the next injectable boom

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Fortune · Jul 1

5 Places Investors Can Hide If the AI Trade Keeps Cracking

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

MarketBeat · Jun 29